The increasing genetic diversity of HIV-1 in the UK, 2002-2010 by Dunn, DT
The increasing genetic diversity of HIV-1 in
the UK, 2002–2010
The UK Collaborative Group on HIV Drug ResistanceCopyright © L
Medical Research
Correspondence to
UK.
E-mail: d.dunn@u
Received: 2 July 2
DOI:10.1097/QAD
ISSN 0269-9370 Q
of the Creative Com
provided it is propeObjective: HIV-1 is typically categorized by genetically distinct viral subtypes. Viral
subtypes are usually compartmentalized by ethnicity and transmission group and, thus,
convey important epidemiological information, as well as possibly influencing the rate
of disease progression. We aim to describe the prevalence and time trends of subtypes
observed among key populations living with HIV-1 in the UK.
Design: Analyses of reverse transcriptase and protease sequences generated from
HIV-1-positive antiretroviral-naive patients as part of routine resistance testing between
2002 and 2010 in all public health and NHS laboratories in the UK.
Methods: Subtype was assigned centrally using the SCUEAL algorithm. Subtyping
results were combined with data from the UK Collaborative HIV Cohort Study and
the UK HIV and AIDS Reporting System. Analyses adjusted for the number of national
HIV-1 diagnoses made each year within demographic subgroups. Viral subtypes were
described overall, over time and by demographic subgroup.
Results: Subtype B diagnoses (39.9%) have remained stable since 2005, whereas
subtype C diagnoses (34.3%) were found to decline in prevalence from 2004. Across
most demographic subgroups, the prevalence of non-B non-C subtypes has increased
over time, in particular novel recombinant forms (9.9%), subtype G (2.7%), and CRF01
AE (2.0%).
Conclusion: HIV-1 subtypes are increasingly represented across all demographic
subgroups and this could be evidence of sexual mixing. Between 2002 and 2010,
the prevalence of novel recombinant forms has increased in all demographic sub-
groups. This increasing genetic diversity and the effect of subtype on disease progression
may impact future HIV-1 treatment and prevention.
 2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28:773–780Keywords: epidemiology, genetic diversity, HIV-1, subtype, subtyping, UKIntroduction
Categorizing HIV-1 into genetic subtypes has been a
powerful epidemiological tool to provide insights into
patterns of HIV-1 transmission, with direct implications
for public health policy. Genetically distinct viral strains
are typically classified as one of nine distinct viral subtypes
and mosaic viruses include 55 circulating recombinant
forms (CRFs), unique recombinant forms (URFs) and
other less well characterized complex structures [1,2].
Alongside epidemiological uses, genetically divergent
strains have biological differences [3], which may impactippincott Williams & Wilkins. Unaut
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susceptibility and response to antiretroviral therapy
(ART) [5] and the rate of disease progression [5–7],
thus potentially bearing on clinical care.
The presence of non-B subtypes has been increasing in
western Europe in recent years as a result of immigration
from sub-Saharan Africa, Asia and eastern Europe [8].
This has led to multiple parallel epidemics within the
UK, and subtypes are strongly associated with ethnicity
and exposure group. In the UK, most HIV-1 group M
subtypes and several CRFs are represented [9] andhorized reproduction of this article is prohibited.
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774 AIDS 2014, Vol 28 No 5subtype B virus, typically associated with MSM, is the
most prevalent. The subtypes observed in the UK have
been recently described for MSM [10] and, historically,
for heterosexuals [11]. We aim to describe the prevalence
and time trends of subtypes observed among major
demographic subgroups affected by HIV-1 in the
UK.Methods
Resistance and clinical data
The UK HIV Drug Resistance Database was established
in 2001 and attempts to collect all resistance tests
conducted within public health and NHS laboratories in
the UK as part of routine clinical care. The resistance tests
analysed in this study used bulk sequencing of the pol
gene, encoding the protease and reverse transcriptase
genes using a variety of in-house and commercial assays.
Resistance tests conducted between 2002 and 2010 were
used; from 2003 UK guidelines recommended that
resistance testing be performed for all drug-naive patients
prior to commencing treatment, and from 2005 [12] for
all newly diagnosed patients.
Subtype was assigned centrally based on the Subtype
ClassificationUsing Evolutionary Algorithms (SCUEAL)
[13], which uses model-based phylogenetic methods to
assign viral subtype. Previous studies have used the REGA
algorithm [14]; however, SCUEAL has been shown to
leave a smaller number of sequences as unclassified, which
are of growing importance [13]. Viruses with mosaic
genomes which do not yet fulfil the criterion to be
established as new CRFs were classified as novel
recombinants. Sub-subtypes such as A1 and A2 or F1
and F2 were combined in our analysis, as were CRFs
other than CRF01_AE, so that categories with small
numbers could be avoided allowing changes over time in
these groups to be analysed.
Demographic data were acquired via annual linkage
(using pseudo-anonymized identifiers such as clinic
number, soundex and date of birth) to the UK
Collaborative HIV Cohort Study (UK CHIC), which
includes patients from 13 of the largest clinics within the
UK [15], and to the HIV and AIDS Reporting System
(HARS) [16], coordinated by Public Health England.
These data include all new diagnoses reported nationally
since the beginning of the epidemic and data from a
national cohort of persons in care updated annually
since 1997.
Analysis
The first ART-naive resistance sample for each patient in
the UK HIV Drug Resistance Database conducted
between 2002 and 2010 was analysed, in which year refers
to the date of sample. Our analyses examined thepyright © Lippincott Williams & Wilkins. Unauthofollowing demographic subgroups: black African women,
black African heterosexual men, white heterosexual men,
white heterosexual women, black African MSM, white
MSM and other MSM. Within each year and demo-
graphic subgroup, the proportion of resistance tests of
each subtype was calculated. To adjust for the overall
number of new diagnoses within the UK, these figures
were then multiplied by the total number of new
diagnoses [17] per year within each demographic
subgroup to give the total number of diagnoses per year
for each subtype. These temporal estimates were
combined for an analysis of subtype by demographic
subgroup and were combined across demographic
subgroups for an analysis of overall temporal trends.
More detailed analyses examined temporal trends by
demographic subgroups and categorized a subtype as
either subtype B, C or non-B, non-C to avoid categories
with small numbers. Differences in subtype prevalence
between groups were tested using the x2 test. All analyses
were conducted in Stata/IC 12.1 (StataCorp LP, College
Station, Texas, USA).Results
Study population
In total, 27 657 ART-naive resistance tests from 2002 to
2010 were available for analysis; this represents 46% of the
60 296 total diagnoses during this period. A total of
21 945 (79%) resistance tests had an associated gender,
ethnicity and probable exposure group; 11 348 (52%)
patients were MSM, 10 567 (48%) had a heterosexual
exposure source and 30 had another exposure source;
11 784 (54%) patients were white, 7374 (34%) were black
African, 847 (4%) were black Caribbean, 458 (2%) were
of another black ethnicity and 1482 (7%) had another
ethnicity. A diagnosis date was available for 20 159 (92%)
patients. Approximately, two-thirds of the resistance
tests were conducted within 3 months of diagnosis
(n¼ 13 385; 66%) and the median (interquartile range,
IQR) time between diagnosis and resistance test date was
25 (7–394) days. The number of tests conducted within
3 months of diagnoses increased from 58% in 2002 to 75%
in 2010, P< 0.001, reflecting national guidelines for
resistance testing.
Demographic information was missing for 5712 resistance
tests, but by adjusting for national diagnoses, any bias in the
differential collection of demographic information will
have been minimized. Patients with missing information
were less likely to have subtype B virus (n¼ 2708; 47.4%
compared with n¼ 11354; 51.7%; P< 0.001) and more
likely to have subtype C virus (n¼ 1628; 28.5% compared
with n¼ 5714; 26.0%; P< 0.001) than patients wherein
this information was known. This suggests that probable
exposure source information is more likely to be missing
from transmission groups with a greater prevalence ofrized reproduction of this article is prohibited.
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.subtype C virus, such as the black African heterosexual
population.
To determine how representative our data was to the UK
epidemic, we compared sites in our study where more
than one third of resistance tests conducted had
demographic data to those that did not. As a result of
the large sample size, significant differences were found
between these sites. There were significantly more male
patients in the sites with more comprehensive demo-
graphic data (61 vs. 59%; P< 0.001) and consequently
there were also differences in the proportion of MSM
(34 vs. 32%; P< 0.001) and black Africans (45 vs. 47%;
P< 0.001). Overall, in absolute terms, these differences
were felt to be small and unlikely to have a large impact on
the prevalence of HIV-1 subtypes.
Overall temporal trends
As is typical of other resource-rich countries, the
predominant viral subtype was found to be subtype B
(n¼ 24 040; 39.9%). Other common subtypes were C
(n¼ 20 678; 34.3%), A (n¼ 3006; 5.0%), novel recom-
binants (n¼ 5989; 9.9%), other CRFs (n¼ 1860; 3.1%),
D (n¼ 1521; 2.5%), G (n¼ 1636; 2.7%) and CRF01 AE
(n¼ 1224; 2.0%). Table 1 presents the temporal trends for
these main subtypes and Fig. 1 illustrates these. Major
changes occurred between 2002 and 2005 as the
estimated number of diagnoses per year increased from
2223 to 2855 for subtype B and for subtype C increased
from 2372 to 2933 followed by a decrease to 2629. After
2006, the number of subtype B diagnoses remained
relatively stable, whereas the number of subtype C
diagnoses continued to decrease.
The number of novel recombinant diagnoses increased
from 461 to 742 per year between 2002 and 2010; the
constituent subtypes found in these recombinants are
shown in Table 3 (Supplementary Digital Content, http://
links.lww.com/QAD/A440) and these novel recombi-
nants often contained fragments of subtypesG (n¼ 575), A
(n¼ 566) and B (n¼ 434). Due to the overall decline in the
number of yearlyHIV-1 diagnoses, this increasemeant that
novel recombinants grew as a proportion of diagnosed
infections and by 2010 accounted for 13.3% of all new
diagnoses. CRF01_AE diagnoses increased from 49 to 173
per year between 2002 and 2006, and remained relatively
stable after this. Other CRFs remained stable throughout
the entire period studied and were mostly consisted of
CRF02_AG (n¼ 250; 46% of other CRFs), CRF15_01B
(n¼ 77; 14%) and CRF6_cpx (n¼ 69; 13%). Finally, the
numbers of patients diagnosed with subtypes A and D
declined disproportionately between 2002 and 2010,
leading to a decrease in the overall proportion of infections
with these subtypes.
Subtype by demographic subgroup
The subtype diversity within demographic subgroups is
shown in Table 2. MSM were found to predominantly,Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 1. Trends in numbers of patients diagnosed by subtype between 2002 and 2010. (a) All subtypes (b) non-B, non-C subtypes
only (using different scale on y-axis).though not exclusively, have subtype B virus (n¼ 18 847;
88.4%). Although MSM had less subtype diversity than
other transmission groups, all subtypes were represented
and there were a notable number of patients infected with
novel recombinant strains (1200; 5.6%). Patients with
heterosexual contact as a probable exposure source had a
much greater variety of subtypes, although there were
gender differences in this group. The most frequent
subtype for both genders was subtype C, although a
greater proportion of women (n¼ 12 789; 55.0%) have
this subtype than men (n¼ 7331; 46.7%; P<0.001).
Subtype B infections were more common in heterosexual
men (n¼ 2947; 18.8%) than women (2246; 9.7%;
P<0.001). Subtype A was also frequent in those with
heterosexual contact as well as a variety of CRFs. Finally,
novel recombinants were frequent in both men andpyright © Lippincott Williams & Wilkins. Unautho
Table 2. Subtype by probable exposure category, 2002–2010.
Subtype Sex between men Me
A 170; 0.8% (83) 1013; 6.4
B 18847; 88.4% (9975) 2947; 18.
C 558; 2.6% (305) 7331; 46.7
D 38; 0.2% (17) 501; 3.2
G 70; 0.3% (37) 570; 3.6
Other pure 71; 0.3% (44) 85; 0.5
CRF01_AE 151; 0.7% (95) 806; 5.1
Other CRF 215; 1.0% (122) 644; 4.1
Novel recombinants 1200; 5.6% (666) 1816; 11.
Total 21 321; 35.4% (11 344) 15 714; 26.
Estimated total number of diagnoses; percentage of exposure category (totwomenwith a probable heterosexual exposure source and
occurred in greater numbers within heterosexuals than
MSM reflecting historical differences in viral diversity
between these populations.
Temporal trends by demographic subgroup
Temporal trends between 2002 and 2010 in subtype
distribution by demographic subgroup are shown in
Figs. 2 and 3 and Table 4 (Supplementary Digital
Content, http://links.lww.com/QAD/A440) shows the
subtype distribution among new diagnoses for hetero-
sexual, black African or white, men and women. The
total number of heterosexual black Africans diagnosed
with HIV-1 fell from 2005/2006, which has similarly
led to a decline in the total number of each subtype
diagnosed. Trends were similar for black African men andrized reproduction of this article is prohibited.
Heterosexual contact
Totaln Women
% (235) 1822; 7.8% (478) 3006 (796)
8% (692) 2246; 9.7% (687) 24 040 (11354)
% (1884) 12789; 55.0% (3525) 20678 (5714)
% (102) 983; 4.2% (195) 1521 (314)
% (188) 995; 4.3% (325) 1636 (550)
% (27) 157; 0.7% (51) 314 (122)
% (187) 267; 1.2% (109) 1224 (391)
% (174) 1001; 4.3% (259) 1860 (555)
6% (534) 2973; 12.8% (949) 5989 (2149)
1% (4023) 23234; 38.5% (6578) 60 270 (21945)
al number of resistance tests). CRF, circulating recombinant form.
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Fig. 2. Trends in subtype over time among black African heterosexuals, 2002–2009. Note different scales on y-axis for women
and men.women with an increase in the proportion of patients
diagnosed with non-B non-C subtypes and a decrease in
the proportion of subtype C. Non-B non-C subtypes
were diagnosed in 485 and 264 black African women and
men, respectively, in 2010. The declining trend was mostCopyright © Lippincott Williams & Wilkins. Unaut
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778 AIDS 2014, Vol 28 No 52002–2004. White heterosexual women are roughly
equally divided between subtype B, C and non-B non-C,
whereas white heterosexual men have proportionately
more subtype B infections (41.1% of overall infections)
and proportionately fewer subtype C infections (22.5% of
overall infections) compared with women (P<0.001).
The number of HIV-1 infections diagnosed amongMSM
increased prior to 2007 and has remained high since then
in all ethnic groups. This has been accompanied by an
increase in the total number of non-B non-C subtypes
diagnosed during this period. Substantial differences in
the subtype make-up of diagnosed MSM by ethnicity are
evident. White MSM and other MSM were chiefly
diagnosed with subtype B, whereas black African MSM
were estimated to have a mixture of subtype B (250;
48.9%), C (85; 16.7%) and non-B, non-C (177; 34.6%).
However, the number and proportion of non-B, non-C
subtypes for white MSM increased markedly from 80
(4.8%) in 2002 to 272 (12.4%) in 2010. This increase was
largely driven by novel recombinant viruses, accounting
for 8.0% of diagnoses among white MSM in 2010. Trends
cannot be discerned for other ethnicities due to the small
numbers diagnosed.Discussion
This study found broad representation of HIV-1 subtypes
within the UK, both overall and within specific
demographic subgroups. Subtype should no longer be
used as a proxy for transmission group when this is
unknown, as has been the case historically, as heterosexual
infections now account for 22% of all subtype B
infections. The increase in non-B non-C subtypes,
particularly novel recombinants among MSM of white
and other ethnicity, demonstrates that there is ongoing
emergence of new novel recombinant forms in the UKor
that these variants are more transmissible. The number of
patients diagnosed with subtype B virus has remained
stable and is the most prevalent subtype in the UK,
whereas the annual number of subtype C HIV-1
diagnoses, has fallen since 2004, reflecting a decline in
new HIV-1 diagnoses in the black African population.
However, it remains the second most prevalent subtype
overall and remains the most common subtype in the
black African population.
Previous UK studies [18] have also found ‘an increasingly
broad range of genetic diversity’ and using phylogenetic
surveillance showed that subtypes typically associated
with infections acquired in East Africa were spreading
among MSM in the UK. Gifford et al. [18] used 10 537
sequences collected between 1996 and 2004, so our study
represents a significant update on the changes in the
prevalence of subtypes that have occurred since then,
while also focusing on temporal trends within probablepyright © Lippincott Williams & Wilkins. Unauthoexposure groups in greater detail. Another UK study [10]
examined the prevalence of non-B subtypes amongMSM
diagnosed from 1980 to 2007, and also found that
nonsubtype B infections were increasing in the UK and
suggested that the association of subtypes to socio-
demographic groups was weakening.
A recent meta-analysis [19] of global data, with 65 913
samples, has concluded that there has been an increase in
the proportion of the subtypes A, F, G, H, CRF01 AE and
CRF02 AG and that the global proportion of all CRFs
has also grown, but did not describe this by demographic
subgroup. However, URFs decreased as a proportion of
infections by 3.1% between 2000–2003 and 2004–2007.
Abecasis et al. [20] used data from the SPREADEuropean
surveillance programme in 2002–2005 and found that
subtype was highly determined by demographic sub-
groups and suggested highly compartmentalized, parallel,
epidemics but only CRF02_AG and subtype F had
significant time trends. Our more recent data suggest that
the effect of increased migration to the UK has led to a
very different epidemic to the rest of Europe, although
the compartmentalization found in SPREAD may have
also broken down since 2005. Other studies [21–23] have
also observed increasing genetic diversity demonstrating
that this is not a phenomenon unique to the UK.
Our study population comprises patients who received a
drug resistance test and may not therefore be representa-
tive of the entire HIV-1-positive population in the UK.
We tried to minimize this bias by only using tests
conducted after 2001 and by accounting for differential
use of resistance testing by ethnicity and exposure group.
However, we could not adjust for the 24% of the HIV-1-
positive population estimated to not yet be aware of their
infection [24]. As a consequence, we may be under-
reporting some non-B subtypes as previous research has
shown that non-African born heterosexuals have a higher
undiagnosed rate of infection compared with MSM (31
compared with 20% [24]). For our temporal trend
analyses, we used the year of sampling for the resistance
test, which might not reflect the date of seroconversion,
although this should not change our main conclusions. It
would have been interesting to have conducted further
analyses comparing UK acquired infections to those
acquired abroad. An indirect method for estimating
country of infection, based on year of migration and
CD4þ cell count at diagnosis, was recently published [25]
and showed that 33% of heterosexuals born abroad
acquired their infection in the UK. However, a similar
analysis was not possible in this study due to incomplete
data on these two variables.
The choice of SCUEAL as the automated subtyping
tool could have influenced our findings compared to
other studies, which have generally used the REGA v2
algorithm. A comparison between the subtype assigned
by SCUEAL and REGA v2 to sequences in this study isrized reproduction of this article is prohibited.
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http://links.lww.com/QAD/A440). Consistent with
another analysis [26], there was strong concordance
between the pure subtypes; the main difference between
the algorithms is that viruses classified as CRF02_AG by
REGA are usually classified as either G, A/G recombi-
nants with alternate breakpoints, or as a complex subtype,
by SCUEAL. The estimated prevalence of these subtypes
would, therefore, have been affected accordingly. Our
analysis uses partial sequences of the pol gene, comprising
approximately 10% of the viral genome, as this is the
region typically sequenced for resistance testing. This
results in underestimates of the prevalence of novel
recombinant forms as mosaic viruses may have break-
points outside of this region. This bias cannot currently be
quantified, but the increasing availability of full length
sequences from next generation sequencing platforms
will allow future quantification of this effect.
The increasing diversity of HIV-1 could be viewed as
evidence that any fitness differences between subtypes are
likely to be small. The fact that distinct demographic
subgroups have overlapping subtypes suggests sexual
linkage between different subgroups, although this can
only be confirmed by conducting further phylogenetic
analyses. The increase in novel recombinants is further
evidence that sexual linkage between demographic
subgroups is occurring for individuals to be simul-
taneously infected with genetically distinct viruses. The
impact this increase in novel recombinants will have on
disease progression, treatment and the development of
drug resistance is not yet known.Acknowledgements
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